

Notice of annual shareholders' meeting in ZymlQ Technology AB

The shareholders of ZymlQ Technology AB are hereby invited to the Annual General Meeting to be held on May 7, 2026, at 3:30 p.m. at the company's premises, Scheeletorget 1 in Lund. Registration for voting begins at 3:00 p.m. and is closed when the meeting is opened.

Right to participate

Shareholders who wish to participate in the Annual General Meeting must be recorded in the share register kept by Euroclear Sweden AB as of April 28, 2026. Shareholders should notify the company of their intent to participate no later than April 30, 2026, at 3:00 p.m. Notification can be made in writing to ZymlQ Technology AB, Scheeletorget 1, 223 63 Lund, Sweden, or via email to michael.christensen@zymiq.com. When notifying the company, please provide your name, address, personal or corporate identity number, daytime telephone number, and, where applicable, the number of assistants (maximum of two). A confirmation will be sent once the notification has been registered.

The meeting will also be broadcast via a digital meeting on Teams (link to be provided separately). Persons who have subscribed for shares that have not yet been registered with the Swedish Companies Registration Office (Bolagsverket) / Euroclear are invited to attend the meeting, but without voting rights. The same applies to shareholders who choose to attend the Annual General Meeting via the digital broadcast.

Nominee-registered shares

To be entitled to participate in the meeting, shareholders whose shares are registered in the name of a nominee must have their shares re-registered in their own name in the share register maintained by Euroclear Sweden AB as of the record date, Tuesday, April 28, 2026. Such registration can be temporary (so-called voting rights registration) and is requested from the nominee in accordance with the nominee's procedures. The nominee may perform such voting rights registration retroactively; however, this must be completed no later than April 30, 2026, to be considered in the preparation of the share register.

Proxies

If a shareholder is to be represented by a proxy, a power of attorney must be issued for the proxy. The power of attorney shall be in writing, signed, and dated by the shareholder. If the shareholder is a legal entity, a copy of the certificate of registration or, if no such document exists, an equivalent authorization document must be attached to the notification. This document must prove the authority of the person signing the power of attorney to appoint a proxy for the legal entity. To facilitate registration at the meeting, the original power of attorney, as well as certificates of registration and other authorization documents, should be received by the Company at the address above no later than 3:00 p.m. on April 30, 2026. If the power of attorney and other authorization

documents have not been submitted in advance, the original power of attorney and other authorization documents must be presented at the meeting. Proxy forms are available from the company and will be sent upon request to shareholders who provide their postal address.

Proposed agenda

1. Opening of the meeting
2. Election of the Chairman of the meeting
3. Preparation and approval of the voting list
4. Election of one or two persons to verify the minutes
5. Determination of whether the meeting has been duly convened
6. Approval of the agenda
7. Address by the Chief Executive Officer (CEO)
8. Presentation of the annual report
9. Resolutions regarding:
 - a. adoption of the income statement and the balance sheet
 - b. allocation of the company's profit or loss according to the adopted balance sheet
 - c. discharge from liability for the members of the Board of Directors and the CEO
10. Resolution on the determination of fees for the Board of Directors and the auditor
11. Resolution on the determination of the number of directors and any deputy directors to be elected by the meeting
12. Election of members of the Board of Directors and any deputy directors
13. Election of the Chairman of the Board
14. Election of auditor
15. Resolution on principles for the Nomination Committee
16. Resolution on authorization for the Board of Directors to issue shares, warrants, or convertibles
17. Authorization for the CEO to make such minor adjustments to the resolutions adopted at the meeting as may be required in connection with registration and execution of the resolutions
18. Closing of the meeting

Proposed resolutions

Dividend (item 9b)

The Board of Directors proposes that no dividend be paid for the financial year 2025.

Election of the Board of Directors, Chairman of the Board, and auditor; determination of fees; and resolution on principles for the appointment of the Nomination Committee (items 2, 10-15)

In preparation for the 2026 Annual General Meeting, the Nomination Committee has consisted of Michael Edelborg Christensen, representing Nordic Consulting Group AB, and Mats Clarsund, representing Clartech AB. Michael Edelborg Christensen has served as the Chairman of the Nomination Committee. The members of the Nomination

Committee represent shareholders controlling approximately 59 percent of the votes in the company. The Nomination Committee proposes that the Annual General Meeting resolve:

that Magnus Steen be elected as Chairman of the meeting,
that the Board of Directors shall consist of five members with no deputy directors,
that Board fees for the 2026 financial year shall be paid to the Board members to meet the requirement of 1.5 income base amounts (2026) during the vesting period for the Board members' employee stock options; otherwise, no Board fees shall be paid for the 2026 financial year,
that Jonas Forsberg, Nicklas Persson, Magnus Steen, Rickard Ånell, and Göran Strömberg be re-elected as members of the Board of Directors,
that Jonas Forsberg be re-elected as Chairman of the Board,
that David Eskilsson, Baker Tilly, be elected as auditor,
that fees to the auditor shall be paid on current account (approved invoice),

that the following principal guidelines shall apply for the appointment of the Nomination Committee:

The Chairman of the Board shall, as soon as the registered ownership structure in the company as of September 30 each year is known, contact the two largest registered shareholders in terms of voting rights and invite them to appoint one member each to the Nomination Committee. Shareholders whose identity does not appear in the share register and who wish to exercise their right shall notify the Chairman of the Board and be able to provide evidence of their ownership. If any invited shareholder declines to appoint a representative, the next largest shareholder in order of size shall be given the opportunity to appoint a representative until two shareholder representatives have been appointed. The members thus appointed shall constitute the Nomination Committee. The Nomination Committee shall appoint a chairman from among its members. The Nomination Committee's term of office extends until a new Nomination Committee has been appointed.

Authorization for the Board of Directors to issue shares, convertibles, or warrants (item 16)

The Board of Directors proposes that the Annual General Meeting authorizes the Board to, on one or more occasions before the next Annual General Meeting, with or without deviation from the shareholders' preferential rights, resolve on the new issue of shares or the issue of convertibles or warrants. Issues may be made against cash payment, contribution in kind, or set-off, or otherwise on conditions as set out in Chapter 2, Section 5, second paragraph, points 1-3 and 5 of the Swedish Companies Act. The number of shares, convertibles, or warrants that may be issued pursuant to the authorization shall not be limited other than as follows from the limits for the share capital and the number of shares set out in the articles of association as applicable at any given time. If the Board of Directors resolves on an issue without preferential rights for the shareholders, the reason shall be to broaden the ownership base, raise or enable the raising of working

capital, increase the liquidity of the share, carry out corporate acquisitions, or raise or enable the raising of capital for corporate acquisitions. In the event of resolutions on issues without preferential rights for the shareholders, the subscription price shall be in line with market conditions at the time of the resolution on the issue.

Other information

For a resolution under item 16 (authorization) to be valid, it must be supported by shareholders representing at least two-thirds of both the votes cast and the shares represented at the meeting.

The annual report, the auditor's report, and other complete supporting documentation for resolutions will be held available at the company's office for at least the period prior to the meeting required by law. The documents will be sent upon request to shareholders who provide their postal address. The Board of Directors and the CEO shall, if any shareholder so requests and the Board of Directors believes that it can be done without material harm to the company or its subsidiaries, provide information at the Annual General Meeting regarding circumstances that may affect the assessment of an item on the agenda and circumstances that may affect the assessment of the company's or a subsidiary's financial situation. The duty to provide information also applies to the company's relationship with subsidiaries and the consolidated financial statements.

Processing of personal data

For information on how your personal data is processed, please see: www.euroclear.com/dam/ESw/Legal/Integritetspolicy-bolagsstammor-svenska.pdf.

For more information, please contact:

Michael Edelborg Christensen, CEO
Phone +46 727 144 166
Email: michael.christensen@zymiq.com

About ZymiQ

ZymiQ Technology AB (publ) is a life science company headquartered in Lund, Sweden and the parent company of the ZymiQ Group. Subsidiaries include ZymiQ Biopharma AB, Sweden and ZymiQ Animal Health LLC, Virginia, USA. The company is also represented by offices in Singapore and Malaysia. ZymiQ develops, manufactures and sells innovative enzyme-based therapeutic and cosmetic products for the well-being of humans and animals. ZymiQ also conducts pioneering research on future alternatives to antibiotics to combat the global challenge of antibiotic resistance, www.zymiq.com

Attachments

[Notice of annual shareholders' meeting in ZymiQ Technology AB](#)